Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818349 | 1.00 | GRM5 (0.39) | GRM5DRD1CYP11B1CYP11B2PTGES2 | |
| SCHEMBL15905925 | 0.93 | GRM5 (0.36) | GRM5DRD1CYP11B1CYP11B2PTGES2 | |
| SCHEMBL19912184 | 0.89 | TNKS (0.34) | GRM5DRD2 | |
| SCHEMBL19009978 | 0.89 | GRM5 (0.33) | GRM5DRD1 | |
| SCHEMBL13681621 | 0.88 | SCN9A (0.37) | GRM5DRD2 | |
| SCHEMBL1224769 | 0.84 | CYP11B1 (0.33) | GRM5DRD1CYP11B1CYP11B2HTR6 | |
| SCHEMBL12446372 | 0.81 | PTGER3 (0.36) | GRM5DRD1CYP11B1CYP11B2POLB | |
| SCHEMBL16449685 | 0.79 | HTR1A (0.32) | — | |
| SCHEMBL14271036 | 0.79 | HTR1A (0.32) | DRD2 | |
| SCHEMBL14652965 | 0.79 | HTR1A (0.32) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267591-A2 | ORGANOMETALLIC COMPOUNDS | Umicore AG & Co. KG (DE) | 2023-11-01 | — | — | EP | claimed |
| WO-2022136049-A2 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2022-06-30 | — | — | WO | claimed |
| EP-2964384-B1 | AQUEOUS HYDROGENATION REACTIONS USING WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION | DUDECHEM GMBH (DE) | 2022-05-04 | — | — | EP | claimed |
| US-9850198-B2 | Process for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds | GRUENENTHAL GMBH (DE) | 2017-12-26 | — | — | US | claimed |
| US-9758457-B2 | Water-insoluble ruthenium catalyst composition for use in aqueous hydrogenation reactions | DEXLECHEM GMBH (DE) | 2017-09-12 | — | — | US | claimed |
| US-20160355454-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | DEXLECHEM GMBH (DE) | 2016-12-08 | — | — | US | claimed |
| US-9433937-B2 | Water-insoluble ruthenium catalyst composition for use in aqueous hydrogenation reactions | DEXLECHEM GMBH (DE) | 2016-09-06 | — | — | US | claimed |
| US-20160008803-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | DEXLECHEM GMBH (DE) | 2016-01-14 | — | — | US | claimed |
| EP-2964384-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | DexLeChem GmbH (DE) | 2016-01-13 | — | — | EP | claimed |
| WO-2014135605-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | JOST SONJA (DE) | 2014-09-12 | — | — | WO | claimed |
| US-8623621-B2 | Method for producing optically active 2-methyl-alkanols | BASF SE (DE) | 2014-01-07 | — | — | US | claimed |
| US-20110045560-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-METHYL-ALKANOLS | BASF AKTIENGESELLSCHAFT (DE) | 2011-02-24 | — | — | US | claimed |
| US-7816107-B2 | Method for producing an optically active 2-methyl-alkane-1-ol from the corresponding 2-methylalk-2-en-1-al, comprising carbonyl-selective reduction, enantioselective hydration and lipase-catalyzed, stereoselective acylation in order to enrich the desired | BASF AKTIENGESELLSCHAFT (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080108117-A1 | Method for Producing an Optically Active 2-Methyl-Alkane-1-Ol from the Corresponding 2-Methylalk-2-En-1-Al, Comprising Carbonyl-Selective Reduction, Enantioselective Hydration and Lipase-Catalyzed Stereoselective Acylation in Order to Enrich the Desired | BASF AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | US | claimed |
| EP-1797191-B1 | PROESS FOR PRODUCING AN OPTICALLY ACTIVE 2-METHYL-ALKANE-1-OLS FROM THE CORRESPONDING 2-METHYLALK-2-EN-1-ALS, COMPRISING A STEP OF ENANTIOSELECTIVE ACYLATION TO ENRICH ONE ENANTIOMER | BASF SE (DE) | 2008-04-02 | — | — | EP | claimed |
| EP-3210965-B2 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240116965-A1 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2024-04-11 | — | — | US | disclosed |
| WO-2007082927-A1 | CHEMICAL TRANSFORMATION PROCESS IN THE PRESENCE OF A RUTHENIUM CATALYST | BASF SE (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007051576-A1 | PROCESS FOR PREPARING SUBSTITUTED DIMETHYL(3-ARYLBUTYL)AMINE COMPOUNDS BY MEANS OF HOMOGENEOUS CATALYSIS | Grünenthal GmbH (DE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070088022-A1 | Tetrahydroquinolines, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088022-A1 | Tetrahydroquinolines, synthesis thereof, and intermediates thereto | HTR2C, HTR3B, HTR2A | GRM5 464/4885DRD1 148/4885CYP11B1 220/4885 |
| US-20160008803-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | KRAS, PWWP2B, WIZ | GRM5 2511/4885DRD1 2550/4885CYP11B1 2045/4885 |
| US-20160355454-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | KRAS, PWWP2B, WIZ | GRM5 2511/4885DRD1 2550/4885CYP11B1 2045/4885 |
| US-20240116965-A1 | ORGANOMETALLIC COMPOUNDS | DDT, PPOX, PDCD2L | GRM5 1973/4885DRD1 765/4885CYP11B1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.